Bulimia Nervosa Market Expected to Show Significant Growth Through 2036, estimates DelveInsight

The leading Bulimia Nervosa Companies are Johnson & Johnson Services, Inc., Dr. Reddy's Laboratories Limited, Lupin Pharmaceuticals, Inc., Aurobindo Pharma, Zydus Cadila, Allergan, Inc., Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Pfizer Inc., Apotex Inc., and Teva Pharmaceutical Industries Ltd.
DelveInsight's Bulimia Nervosa Market Insights, Epidemiology and Market Forecast 2036 provides the current and forecast market analysis, individual leading Bulimia Nervosa Companies market shares, challenges, Bulimia Nervosa Market Drivers, barriers, trends, and key market Bulimia Nervosa companies in the market.

To read more about the latest highlights related to the Bulimia Nervosa Market, get a snapshot of the key highlights entailed in the Market Report @https://www.delveinsight.com/sample-request/bulimia-nervosa-market?utm_source=abnewswire&utm_medium=pr&utm_campaign=kkpr

Key Takeaways from the Bulimia Nervosa Market Report

*
.In May 2025, CVS Health announced additional efforts to streamline its network and optimize store operations, including the closure of certain underperforming pharmacy locations while expanding pharmacy service offerings in areas with higher demand.

*
In October 2025, CVS Health published its annual pharmacy outlook report, emphasizing the continued leadership of retail pharmacies within the U.S. prescription market. The report also noted significant growth in the dispensing of medications for chronic conditions, including antidepressants and other mental health treatments.

*
In September 2025, the University of Oxford launched "Digital C BTe," a structured digital cognitive behavioral therapy program designed for eating disorders such as bulimia nervosa. The initiative aims to improve access to treatment across the Asia-Pacific region and other underserved areas.

*
In September 2024, Lupin Limited secured U.S. FDA approval for Fluoxetine Tablets USP (10 mg, 20 mg, and 60 mg), broadening its portfolio of generic SSRIs used in the treatment of bulimia nervosa. Fluoxetine continues to be the only FDA-approved medication specifically indicated for bulimia nervosa in the United States.

*
In October 2025, Teva Pharmaceutical Industries Ltd received FDA approval to expand the use of UZEDY (long-acting risperidone injection) for the treatment of bipolar I disorder, further strengthening its central nervous system (CNS) portfolio and supporting psychiatric care services across the U.S. healthcare system.

*
Bulimia Nervosa is a serious psychiatric eating disorder characterized by recurrent episodes of binge eating followed by compensatory behaviors such as self-induced vomiting, excessive exercise, fasting, or misuse of laxatives. The disorder is strongly associated with distorted body image and emotional distress.

*
According to epidemiological data, the lifetime prevalence rates for bulimia nervosa ranged from 0.3 -- 4.6% in females and from 0.1 -- 1.3% in males, with one-year prevalence of 0.32% for females and 0.05% for males.

*
During the period from 1990 to 2021, the number of individuals affected by bulimia nervosa increased by 67%, rising from 7,416,420 cases to 12,367,024 cases, reflecting growing disease incidence globally.

*
The leading Bulimia Nervosa Companies such as Johnson & Johnson Services, Inc., Dr. Reddy's Laboratories Limited, Lupin Pharmaceuticals, Inc., Aurobindo Pharma, Zydus Cadila, Allergan, Inc., Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Pfizer Inc., Apotex Inc., and Teva Pharmaceutical Industries Ltd.

To know more about why the 7MM regions are leading the market growth in the Bulimia Nervosa Market, get a snapshot @ Bulimia Nervosa Market Outlook-https://www.delveinsight.com/sample-request/bulimia-nervosa-market?utm_source=abnewswire&utm_medium=pr&utm_campaign=kkpr

Bulimia Nervosa Market Dynamics

The Bulimia Nervosa market is experiencing gradual but meaningful growth driven by increasing awareness of eating disorders, rising diagnosis rates, expanding mental health infrastructure, and growing demand for integrated psychiatric care. The current treatment landscape is primarily multidisciplinary, combining psychotherapy, nutritional rehabilitation, behavioral interventions, and pharmacological management to achieve symptom control and relapse prevention. Cognitive behavioral therapy (CBT) remains the clinical gold standard and is widely recommended as the first-line intervention. Key factors such as growing mental health awareness, public awareness campaigns, educational initiatives reducing stigma associated with eating disorders, and the expansion of digital health and telemedicine services are creating a favorable environment for sustained market growth. Additionally, sociocultural pressures related to body image, dieting culture, and mental health challenges continue to increase the number of diagnosed cases and drive demand for therapeutic interventions from 2022 to 2036.

Bulimia Nervosa Market Segmentation Analysis

Bulimia Nervosa Market segmentation encompasses current treatment practices, marketed therapies, and off-label treatment options, with coverage across the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. The market is analyzed by epidemiology segments including total diagnosed prevalent cases, gender-specific diagnosed prevalent cases, age-specific diagnosed prevalent cases, and total treated cases of bulimia nervosa. Treatment approaches in the market are segmented by region and therapy type, reflecting variations in clinical practices across different geographies. The report provides comprehensive insight into the current treatment landscape, including cognitive behavioral therapy, interpersonal therapy, dialectical behavioral therapy, family-based therapy, nutritional counseling, and digital mental health programs used alongside pharmacological management.

Get a sneak peek at the Bulimia Nervosa Market Dynamics @ Bulimia Nervosa Market Dynamics Analysis-https://www.delveinsight.com/sample-request/bulimia-nervosa-market?utm_source=abnewswire&utm_medium=pr&utm_campaign=kkpr

Bulimia Nervosa Companies

Johnson & Johnson Services, Inc., Dr. Reddy's Laboratories Limited, Lupin Pharmaceuticals, Inc., Aurobindo Pharma, Zydus Cadila, Allergan, Inc., Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd, and others.

Bulimia Nervosa Market Drivers

The demand for Bulimia Nervosa therapeutics is rising significantly, driven by multiple key factors. The rising prevalence of eating disorders, particularly among adolescents and young adults, is one of the major drivers of market growth. Growing mental health awareness through public awareness campaigns, mental health advocacy programs, and educational initiatives is reducing stigma associated with eating disorders, encouraging more patients to seek professional treatment. The expansion of digital health and telemedicine services, including digital therapeutics, telepsychiatry, mental health apps, and remote counseling services, is improving patient access to treatment, especially in underserved regions. Additionally, societal beauty standards and social media exposure emphasizing thinness contribute significantly to body dissatisfaction and unhealthy eating behaviors, increasing vulnerability to bulimia nervosa particularly among younger populations. These factors, combined with expanding mental health infrastructure and growing recognition of eating disorders as serious psychiatric conditions, are creating a favorable environment for sustained market growth during the forecast period.

Which MedTech key players in the Bulimia Nervosa Market are set to emerge as the trendsetter? Explore @ Bulimia Nervosa Companies-https://www.delveinsight.com/sample-request/bulimia-nervosa-market?utm_source=abnewswire&utm_medium=pr&utm_campaign=kkpr

Scope of the Bulimia Nervosa Market Report

*
Coverage- 7MM

*
Study Period- 2022-2036

*
Forecast Period- 2026-2036

*
Bulimia Nervosa Companies- Johnson & Johnson Services, Inc., Dr. Reddy's Laboratories Limited, Lupin Pharmaceuticals, Inc., Aurobindo Pharma, Zydus Cadila, Allergan, Inc., Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd, and others.

Interested in knowing the Bulimia Nervosa Market by 2036? Click to get a snapshot of the Bulimia Nervosa Market Trends-https://www.delveinsight.com/sample-request/bulimia-nervosa-market?utm_source=abnewswire&utm_medium=pr&utm_campaign=kkpr

Table of Contents

*
Key Insights

*
Report Introduction

*
Executive Summary

*
Key Events

*
Epidemiology and Market Forecast Methodology

*
Bulimia Nervosa Market Overview at a Glance

*
Disease Background and Overview of Bulimia Nervosa

*
Treatment

*
Epidemiology and Patient Population of Bulimia Nervosa

*
Patient Journey

*
Bulimia Nervosa: 7MM Analysis

*
Unmet Needs of Bulimia Nervosa

*
SWOT Analysis of Bulimia Nervosa

*
KOL Views of Bulimia Nervosa

*
Market Access and Reimbursement

*
Appendix

*
DelveInsight Capabilities

*
Disclaimer

*
About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=bulimia-nervosa-market-expected-to-show-significant-growth-through-2036-estimates-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.